| Compound | Orexin B |
|---|---|
| Category | Endogenous hypocretin |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Orexin B is catalogued here as a endogenous hypocretin and graded at the "Minimal evidence" evidence tier. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
The shorter-lived of the two hypocretin neuropeptides, sharing wakefulness regulation biology with Orexin A but with different receptor affinity and stability.
Mechanism of Action
Orexin B preferentially activates the OX2 receptor involved in sleep-wake stabilization.
Research and Evidence
Biology well characterized in animals; no meaningful therapeutic administration data in humans.
Safety and Side Effects
No human administration safety data.
Frequently Asked Questions
What is the evidence tier of Orexin B?
Orexin B is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Orexin B an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Orexin B?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for orexin B studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.